The nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is activated by peroxisome proliferators (PP), a large class of structurally diverse xenobiotic chemicals, hypolipidemic drugs, and endogenous lipids. PPARα alters the transcriptional programs of genes whose functions include lipid metabolism, inflammation, cell fate, and stress responses in liver, heart, kidney, and skin. Many of these genes are also under control of PPARα in the absence of exogenous peroxisome proliferator exposure. Mice that lack PPAR α (PPARα-null mice) exhibit a number of defects in lipid metabolism and accumulate lipids in the liver. Here, we compared the age-dependent lesions in the liver, kidney, and heart in PPARα-null mice with those observed in wild-type SV129 mice, in the absence of exogenous chemical exposure. Groups of mice were sacrificed, at 6, 12, 18, 21, or 24 months of age, or allowed to age until moribund or found dead. PPARα-null mice had decreased longevity, due to a variety of causes. Statistically significant differences in the occurrence of a number of lesions between strains was observed. Hepatocellular carcinomas and multiple hepatocellular adenomas occurred in PPARα-null mice but not wild type mice. Various nonneoplastic spontaneous aging lesions occurred at higher incidence, shorter latency, or increased severity in PPARα-null mice compared with wild-type mice. In the liver, these included vacuolated hepatocytes and sinusoidal cells and mixed cell inflammation. The kidneys of PPARα-null mice exhibited higher incidences and severities of cortical mineralization. Minimal myocardial mineralization occurred at a higher incidence in PPARα-null mice. Our results imply that PPARα delays the development of some spontaneous lesions associated with aging in the liver, kidney, and heart of SV129 mice.
Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., and Gonzalez, F.J. (1998). Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem273, 5678—84.
3.
Barger, P.M., Browning, A.C., Garner, A.N., and Kelly, D.P. (2001). p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J Biol Chem276, 44495—501.
4.
Botts, S., Jokinen, M., Gaillard, E.T., Elwell, M.R., and Mann, P.C. (1999). Salivary, harderian, and lacrimal glands. In Pathology of the Mouse (R. R. Maronpot , ed.), pp. 49—79. Cache River Press, Vienna, IL.
5.
Cattley, R.C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B.G., Marsman, D.S., Pastor, T.A., Popp, J.A., Robinson, D.E., Schwetz, B., Tugwood, J., and Wahli, W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol27 (1, Pt. 2), 47—60.
6.
Cattley, R.C., Marsman, D.S., and Popp, J.A. (1989). Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver. Cancer Res49, 3246—51.
7.
Chao, C., Youssef, J., Rezaiekhaleigh, M., Birnbaum, L.S., and Badr, M. (2002). Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor α, but not peroxisome proliferator-activated receptor alpha. Mech Ageing Dev123, 1469— 76.
8.
Chen, C., Hennig, G.E., Whiteley, H.E., Corton, J.C., and Manautou, J.E. (2000). Peroxisome proliferator-activated receptor α-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci57, 338—44.
9.
Coffer, P. (2003). OutFOXing the grim reaper: novel mechanisms regulating longevity by forkhead transcription factors. Sci. STKE39, PE39.
10.
Corton, J.C., Anderson, S.P., and Stauber, A. (2000). Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol49, 491—518.
11.
Corton, J.C., Fan, L.-Q., Brown, S., Anderson, S.P., Bocos, C., Cattley, R.C., Mode, A., and Gustafsson, J.-A. (1998). Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol Pharmacol54, 463— 73.
12.
Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J., and Wahli, W. (1996). The PPARα-leukotriene B4 pathway to inflammation control. Nature384, 39—43.
13.
Duplus, E., and Forest, C. (2002). Is there a single mechanism for fatty acid regulation of gene transcription? Biochem Pharmacol64, 893—901.
14.
Eaton, G.J., Custer, R.P., Johnson, F.N., and Stabenow, K.T. (1978). Dystrophic cardiac calcinosis in mice. Am J Pathol90, 173—86.
15.
Fan, L.-Q., Coley, J., Miller, R.T., Cattley, R.C., and Corton, J.C. (2003). Opposing mechanisms of NADPH-cytochrome P450 oxidoreductase regulation by peroxisome proliferators. Biochem Pharmacol65, 949—59.
16.
Hamet, P., and Tremblay, J. (2003). Genes of aging. Metabolism52, 5—9.
17.
Harada, T., Enomoto, A., Boorman, G.A., and Maronpot, R.R. (1999). Liver and gall bladder. In Pathology of the Mouse (R. R. Maronpot, ed.), pp. 119—83. Cache River Press, Vienna, IL.
18.
Hihi, A.K., Michalik, L., and Wahli, W. (2002). PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci59, 790—8.
19.
HogenEsch, H., Gruys, E., and Higuchi, K. (1996). Senile amyloidosis. In Pathobiology of the Aging Mouse (U. Mohr, D. L. Dungworth, C. C. Capen, W. W. Carlton, J. P. Sundberg, and J. M. Ward, eds.), Vol. 1, pp. 237—44. ILSI Press, Washington, DC.
20.
Iemitsu, M., Miyauchi, T., Maeda, S., Tanabe, T., Takanashi, M., IrukayamaTomobe, Y., Sakai, S., Ohmori, H., Matsuda, M., and Yamaguchi, I. (2002). Aging-induced decrease in the PPAR-α level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol283, H1750—60.
21.
Jaenisch, R., and Bird, A. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Gen Suppl33, 245—54.
22.
Jones, D.C., Manning, B.M., and Daynes, R.A. (2002). A role for the peroxisome proliferator-activated receptor α in T-cell physiology and ageing immunobiology. Proc Nutr Soc61, 363—9.
23.
Kippenberger, S., Loitsch, S.M., Grundmann-Kollmann, M., Simon, S., Dang, T.A., Hardt-Weinelt, K., Kaufmann, R., and Bernd, A. (2001). Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation . J Invest Dermatol117, 1430— 6.
24.
Klaunig, J.E., Babich, M.A., Baeckte, K.P., Cook, J.C., Corton, C., David, R.M., DeLuca, J.G., Lai, D.Y., McKee, R.H., Peters, J.M., Roberts, R.A., and Fenner-Crisp, P.A. (2003). PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol33, 655—780.
25.
Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., and Gonzalez, F.J. (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol15, 3012—22.
26.
Lock, E.A., Mitchell, A.M., and Elcombe, C.R. (1989). Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol29, 145—63.
27.
Longo, V.D., and Finch, C.E. (2003). Evolutionary medicine: from dwarf model systems to healthy centenarians? Science299, 1342—6.
28.
Mehendale, H.M. (2000). PPAR-α: a key to the mechanism of hepatoprotection by clofibrate. Toxicol Sci57, 187—90.
29.
Motojima, K., Peters, J.M., and Gonzalez, F.J. (1997). PPAR α mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Biochem Biophys Res Commun230, 155—8.
30.
Parsons, P.A. (2003). From the stress theory of aging to energetic and evolutionary expectations for longevity. Biogerontology4, 63—73.
31.
Peckham, J.C., and Heider, K. (1999) Skin and subcutis. In Pathology of the Mouse (R. R. Maronpot, ed.), pp. 555—612. Cache River Press, Vienna, IL.
32.
Perichon, R., and Bourre, J.M. (1995). Liver peroxisomal fatty acid oxidizing system during aging in control and clofibrate-treated mice. Biochem Mol Biol Int37, 475—80.
33.
Perichon, R., and Bourre, J.M. (1996). Aging-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev87, 115— 26.
34.
Peters, J.M., Cattley, R.C., and Gonzalez, F.J. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis18, 2029—33.
35.
Peters, J.M., Zhou, Y.C., Ram, P.A., Lee, S.S., Gonzalez, F.J., and Waxman, D.J. (1996). Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 β-sulfate. Mol Pharmacol50, 67—74.
36.
Portilla, D., Dai, G., Peters, J.M., Gonzalez, F.J., Crew, M.D., and Proia, A.D. (2000). Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol278, F667—75.
37.
Poynter, M.E., and Daynes, R.A. (1998). Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem273, 32833—41.
38.
Qi, C., Zhu, Y., and Reddy, J.K. (2000). Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys32, 187—204.
39.
Rao, M.S., Peters, J.M., Gonzalez, R.J., and Reddy, J.K. (2002). Hepatic regeneration in peroxisome proliferator-activated receptor α-null mice after partial hepatectomy. Hepatol Res22, 52—7.
40.
Seely, J.C. (1999). Kidney. In Pathology of the Mouse (R. R. Maronpot, ed.), pp. 207—34. Cache River Press, Vienna, IL.
41.
Shankar, K., Vaidya, V.S., Corton, J.C., Bucci, T.J., Liu, J., Waalkes, M.P., and Mehendale, H.M. (2003). Activation of PPAR-α in streptozotocininduced diabetes is essential for resistance against acetaminophen toxicity. FASEB J17, 1748—50.
42.
Sharpless, N.E., and DePinho, R.A. (2004). Telomeres, stem cells, senescence, and cancer . J Clin Invest113, 160—8.
43.
Sheldon, W.G., Bucci, T.J., Blackwell, B., and Turturro, A. (1996). Effect of ad libitum feeding and 40% feed restriction on body weight, longevity, and neoplasms in B6C3F1, C57BL6, and B6D2F1 mice . In Pathobiology of the Aging Mouse (U. Mohr, D. L. Dungworth, C. C. Capen, W. W. Carlton , J. P. Sundberg, and J. M. Ward, eds.), Vol. 1, pp. 21—6. ILSI Press, Washington, DC.
44.
Sivarajah, A., Chatterjee, P.K., Hattori, Y., Brown, P.A., Stewart, K.N., Todoravic, Z., Mota-Filipe, H., and Thiemermann, C. (2002). Agonists of peroxisome-proliferator activated receptor-α (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit8, BR532—9.
45.
Stebbins, K.E., Bond, D.M., Novilla, M.M., and Reasor, M.J. (2002). Spinosad insecticide: subchronic and chronic toxicity and lack of carcinogenicity in CD-1 mice. Toxicol Sci65, 276—87.
46.
Sundberg, J.P., Sundberg, B.A., and King L.E. (1996) Cutaneous changes in commonly sed inbred mouse strains and mutant stocks. In Pathobiology of the Aging Mouse (U. Mohr, D. L. Dungworth, C. C. Capen, W. W. Carlton, J. P. Sundberg and J. M. Ward, eds.), Vol. 2, pp. 325—37. ILSI Press, Washington, DC.
47.
Ward, J.M., Anver, M.R., Mahler, J.F., and Devor-Henneman, D.E. (2000). Pathology of mice commonly used in genetic engineering (C57BL/6; 129; B6,129; and FVB/N). In Pathology of Genetically Engineered Mice (J. M. Ward, J. F. Mahler, R. R. Maronpot, J. P. Sundberg , and R. M. Fredrickson eds.), pp. 161—79. Iowa State University Press, Ames, Iowa.
48.
Ward, J.M., Yoon, M., Anver, M.R., Haines, D.C., Kudo, G., Gonzalez, F.J., and Kimura, S. (2001). Hyalinosis and Ym1/Ym2 gene expression in the stomach and respiratory tract of 129S4/SvJae and wild-type and CYP1A2-null B6, 129 mice. Am J Pathol158, 323—32.
49.
Warner, H.R., and Sierra, F. (2003). Models of accelerated ageing can be Informative about the molecular mechanisms of ageing and/or age-related pathology. Mech Ageing Devel124, 581—7.
50.
Watanabe, K., Fujii, H., Takahashi, T., Kodama, M., Aizawa, Y., Ohta, Y., Ono, T., Hasegawa, G., Naito, M., Nakajima, T., Kamijo, Y., Gonzalez, F.J., and Aoyama, T. (2000). Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem275, 22293— 9.
51.
Wheeler, M.D., Smutney, O.M., Check, J.F., Rusyn, I., Schulte-Hermann, R., and Thurman, R.G. (2003). Impaired Ras membrane association with activation in PPARα knockout mice after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol284, G302—12.
52.
Youssef, J., and Badr, M. (1999). Biology of senescent liver peroxisomes: role in hepatocellular aging and disease. Environ Health Perspect107, 791—7.
